Evotec Future Growth

Future criteria checks 4/6

Evotec is forecast to grow earnings and revenue by 51.7% and 12.9% per annum respectively. EPS is expected to grow by 48.2% per annum. Return on equity is forecast to be 9.3% in 3 years.

Key information

51.7%

Earnings growth rate

48.2%

EPS growth rate

Life Sciences earnings growth	21.7%
Revenue growth rate	12.9%
Future return on equity	9.3%
Analyst coverage	Good
Last updated	26 Apr 2024

Recent future growth updates

Recent updates

Evotec SE's (ETR:EVT) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 21

Earnings and Revenue Growth Forecasts

XTRA:EVT - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	1,190	113	221	278	8
12/31/2025	1,054	74	112	221	11
12/31/2024	881	10	-16	144	8
12/31/2023	781	-84	-180	36	N/A
9/30/2023	821	-95	-192	-18	N/A
6/30/2023	798	-103	-247	-43	N/A
3/31/2023	779	-117	-54	137	N/A
12/31/2022	751	-176	24	206	N/A
9/30/2022	698	-180	121	297	N/A
6/30/2022	684	2	194	322	N/A
3/31/2022	650	90	58	183	N/A
12/31/2021	618	216	3	122	N/A
9/30/2021	571	247	-58	86	N/A
6/30/2021	541	112	-50	93	N/A
3/31/2021	515	42	-99	20	N/A
12/31/2020	501	6	-54	45	N/A
9/30/2020	485	14	-4	62	N/A
6/30/2020	470	35	0	46	N/A
3/31/2020	462	42	43	82	N/A
12/31/2019	446	38	10	42	N/A
9/30/2019	419	61	1	29	N/A
6/30/2019	404	77	46	74	N/A
3/31/2019	398	94	109	139	N/A
12/31/2018	375	84	128	156	N/A
9/30/2018	370	63	109	135	N/A
6/30/2018	338	31	54	80	N/A
3/31/2018	294	20	-2	19	N/A
12/31/2017	264	23	-7	11	N/A
9/30/2017	215	28	N/A	64	N/A
6/30/2017	193	35	N/A	73	N/A
3/31/2017	178	36	N/A	74	N/A
12/31/2016	165	28	N/A	67	N/A
9/30/2016	160	18	N/A	5	N/A
6/30/2016	148	6	N/A	-6	N/A
3/31/2016	144	17	N/A	-2	N/A
12/31/2015	128	17	N/A	16	N/A
9/30/2015	119	12	N/A	19	N/A
6/30/2015	104	11	N/A	23	N/A
3/31/2015	93	-4	N/A	9	N/A
12/31/2014	89	-7	N/A	-4	N/A
9/30/2014	85	-29	N/A	6	N/A
6/30/2014	89	-25	N/A	2	N/A
3/31/2014	86	-27	N/A	1	N/A
12/31/2013	86	-25	N/A	7	N/A
9/30/2013	83	-10	N/A	8	N/A
6/30/2013	82	-4	N/A	12	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: EVT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.7%).

Earnings vs Market: EVT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EVT is expected to become profitable in the next 3 years.

Revenue vs Market: EVT's revenue (12.9% per year) is forecast to grow faster than the German market (5.5% per year).

High Growth Revenue: EVT's revenue (12.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: EVT's Return on Equity is forecast to be low in 3 years time (9.3%).

Evotec Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Evotec SE Provides Earnings Guidance for the Year 2024

Price target decreased by 7.5% to €23.00

Price target decreased by 7.6% to €23.67

Price target decreased by 8.3% to €24.88

Price target decreased by 9.1% to €27.14

Evotec SE Provides Revenue Guidance for the Full Year 2023

Recent updates

Evotec SE announced delayed 20-F filing

Full year 2023 earnings: EPS misses analyst expectations

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

Price target decreased by 7.5% to €23.00

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Price target decreased by 7.6% to €23.67

Price target decreased by 8.3% to €24.88

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Price target decreased by 9.1% to €27.14

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.16 loss in 2Q 2022)

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Evotec SE, Annual General Meeting, Jun 20, 2023

Is There An Opportunity With Evotec SE's (ETR:EVT) 37% Undervaluation?

Price target decreased by 8.1% to €24.93

Price target decreased by 9.8% to €24.73

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Price target decreased to €26.72

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Price target decreased to €30.94

Consensus forecasts updated

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Price target decreased to €32.50

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Consensus forecasts updated

Consensus EPS estimates have been upgraded.

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec SE Revises Revenue Guidance for the Full Year 2022

Consensus forecasts updated

Evotec (ETR:EVT) Seems To Use Debt Quite Sensibly

Now 20% undervalued

Evotec SE (XTRA:EVT) completed the acquisition of Rigenerand S.R.L. from Xyence Capital SGR and others.

Now 22% undervalued after recent price drop

Evotec Se Appoints Camilla Macapili Languille as New Member of Supervisory Board

Now 22% undervalued after recent price drop

Evotec SE (XTRA:EVT) agreed to acquire Rigenerand S.R.L. for €25 million.

Investor sentiment improved over the past week

Is Now The Time To Look At Buying Evotec SE (ETR:EVT)?

Evotec SE Confirms Revenue Guidance for 2022

Is Evotec (ETR:EVT) A Risky Investment?

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec Se Provides Revenue Guidance for 2022

Consensus forecasts updated

Do Evotec's (ETR:EVT) Earnings Warrant Your Attention?

Now 21% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Evotec SE Announces That the Company Has Been Informed by Bayer About A Decision to Discontinue the Development of the Investigational P2X3 Receptor Antagonist Eliapixant

Evotec SE to Report Q1, 2022 Results on May 11, 2022

At €36.91, Is It Time To Put Evotec SE (ETR:EVT) On Your Watch List?

Evotec Receives € 7.5 Million Grant for Development of Covid-19 Therapeutic from German Federal Ministry of Education and Research

Price target increased to €42.92

Consensus EPS estimates increase to €1.40